Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
antineoplaston A10 + antineoplaston AS2-1
- Development stage
- Unknown
- Lead developer
- Burzynski Research Institute
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Antineoplaston A10 + antineoplaston AS2-1 is a combination therapy consisting of synthetic peptides and amino acid derivatives. Antineoplaston A10 (3-phenylacetylamino-2,6-piperidinedione) and AS2-1 (a 4:1 mixture of phenylacetic acid and phenylacetylglutamine) are claimed to function as part of a biochemical defense system that induces differentiation in neoplastic cells. The therapy is administered intravenously or orally and has been primarily investigated for brain tumors and other cancers. The proposed mechanisms include DNA intercalation, cell cycle inhibition, apoptosis stimulation, and protein synthesis inhibition.
- Brand names
- Atengenal + Astugenal
- Other names
- Antineoplastons A10/AS2-1Antineoplastons therapy
02
Targets
NeuraminidaseDNA
Beyond the preview
Go deeper on antineoplaston A10 + antineoplaston AS2-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on antineoplaston A10 + antineoplaston AS2-1.